How to Get Lunesta (Eszopiclone) in New Hampshire

What Is Eszopiclone and Why New Hampshire Patients Request It

Eszopiclone is the S-enantiomer of zopiclone, approved by the FDA in December 2004 for the treatment of insomnia [1]. Unlike older sedative-hypnotics, eszopiclone showed durable efficacy across six months of nightly use without evidence of tolerance developing in controlled trials [2]. The drug binds selectively to GABA-A receptor complexes containing alpha-1 and alpha-2 subunits, producing sleep-onset and sleep-maintenance effects [3].

New Hampshire sleep specialists and primary care physicians prescribe eszopiclone because the clinical evidence base is unusually strong for a sleep drug. In a landmark 6-month, randomized, double-blind trial by Krystal et al. (N=788), patients taking eszopiclone 3 mg nightly reported significant improvements in sleep latency, total sleep time, and daytime functioning compared with placebo, with no evidence of tolerance through week 24 [2]. Sleep latency decreased by a mean of 30 minutes versus 14 minutes in the placebo group (P<0.001), and wakefulness after sleep onset fell by 22 minutes versus 8 minutes [2].

New Hampshire has a documented insomnia burden. The CDC's Behavioral Risk Factor Surveillance System found that approximately 35.2% of U.S. adults report sleeping fewer than 7 hours per night [4], and NH-specific data align closely with that national figure. Chronic insomnia disorder, defined as difficulty initiating or maintaining sleep at least 3 nights per week for at least 3 months by the American Academy of Sleep Medicine (AASM) [5], affects an estimated 10% to 15% of adults [6].

Eszopiclone is manufactured by Sunovion under the brand name Lunesta; multiple FDA-approved generic versions have been available since 2014 [1]. Generic eszopiclone tablets (1 mg, 2 mg, 3 mg) typically retail for $15 to $45 per 30-tablet supply at New Hampshire pharmacies when purchased without insurance.

How New Hampshire Regulates Eszopiclone Prescribing

Eszopiclone is a Schedule IV controlled substance under the federal Controlled Substances Act [7]. New Hampshire mirrors federal scheduling under NH RSA 318-B. Schedule IV status means a prescriber must hold a valid DEA registration in addition to a New Hampshire license [7].

New Hampshire allows telehealth prescribing of Schedule IV substances under NH RSA 329:1-d, provided the prescriber conducts a synchronous audio-video consultation that meets the standard of care for an in-person visit [8]. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 normally requires an in-person evaluation before a controlled substance prescription is issued via telemedicine [9]. A DEA rule that took effect in May 2023 extended pandemic-era flexibilities, permitting DEA-registered telemedicine practitioners to prescribe Schedule III and IV controlled substances without a prior in-person visit under specified conditions, including audio-video presence and a valid prescriber-patient relationship [10]. This means a New Hampshire patient can complete a first visit over video and receive an eszopiclone prescription without traveling to a clinic.

Prescriptions for Schedule IV drugs in New Hampshire must be transmitted to a pharmacy through the New Hampshire Prescription Drug Monitoring Program (NH PDMP), operated by the NH Department of Health and Human Services [11]. Prescribers are required to query the PDMP before issuing a controlled substance prescription for a new patient [11].

Eszopiclone prescriptions in New Hampshire may be written for up to a 90-day supply with no refills on the original prescription; each refill requires a new prescription [7]. Fax and electronic transmission are both permitted; paper prescriptions require a tamper-resistant format [11].

Who Can Prescribe Lunesta in New Hampshire

New Hampshire MDs, DOs, NPs with full prescriptive authority, and PAs operating under a supervising physician agreement may all prescribe eszopiclone [8]. New Hampshire is a full-practice-authority state for nurse practitioners, meaning NPs do not need physician oversight to prescribe Schedule IV substances after completing their collaborative practice requirement period [8].

Psychiatrists, sleep medicine specialists, primary care physicians, and internal medicine physicians most commonly prescribe eszopiclone in NH. Any licensed prescriber with an active DEA number in New Hampshire can write the prescription, provided their scope of practice covers insomnia management.

Telehealth platforms that operate in New Hampshire and hold NH prescriber licenses can legally issue eszopiclone prescriptions after a qualifying synchronous video visit [10]. The prescriber must be licensed in New Hampshire regardless of where they are physically located during the visit.

Telehealth Options for Lunesta in New Hampshire

New Hampshire residents can access eszopiclone prescriptions through several telehealth pathways. The visit must include a live, two-way audio-video interaction; asynchronous questionnaire-only consultations do not satisfy DEA requirements for Schedule IV substances [10].

A qualifying telehealth visit for insomnia typically covers:

• Sleep history (onset, duration, frequency of symptoms)
• Screening for obstructive sleep apnea (OSA) using validated tools such as the STOP-BANG questionnaire [12]
• Review of current medications and potential interactions
• Psychiatric screening, given the comorbidity between insomnia and mood disorders [6]
• Discussion of cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment per AASM guidelines [5]

The AASM explicitly recommends CBT-I as the first-line treatment for chronic insomnia disorder before pharmacotherapy [5]. Prescribers following AASM guidance will typically document that CBT-I was discussed, offered, or attempted before issuing a standing eszopiclone prescription [5].

The HealthRX clinical team uses a three-step intake framework for eszopiclone telehealth consults in New Hampshire:

1. Sleep diary review (7-day minimum) submitted before the visit via patient portal
2. STOP-BANG OSA screen completed asynchronously; scores of 5 or higher trigger a referral recommendation for polysomnography before pharmacotherapy
3. Synchronous video visit for clinical assessment, shared decision-making, and PDMP query

This sequence allows the prescriber to make a fully informed prescribing decision within a single billable visit while satisfying DEA and NH PDMP requirements.

Most telehealth platforms serving New Hampshire can generate and transmit an e-prescription to any NH-licensed pharmacy within minutes of visit completion. Patients typically receive their first fill within 24 to 48 hours of the appointment.

Eszopiclone Dosing for New Hampshire Patients

The FDA-approved dosing for eszopiclone is 1 mg at bedtime for adults, with optional titration to 2 mg or 3 mg based on clinical response and tolerability [1]. The FDA specifically recommends 1 mg as the starting dose for all adults after a 2014 label update prompted by next-morning impairment data [1].

Women and patients over age 65 are advised to use no more than 2 mg per night because pharmacokinetic studies showed higher plasma concentrations in these groups at equivalent doses, increasing the risk of next-day psychomotor impairment [1]. The FDA label states: "The recommended dose for non-elderly adults is 1 mg immediately before bedtime. Increasing the dose to 2 mg or 3 mg may improve sleep maintenance. The total dose should not exceed 3 mg." [1]

Eszopiclone should be taken immediately before bed. Patients should not take it unless they have at least 7 to 8 hours available for sleep [1]. Taking it with a high-fat meal delays absorption and reduces peak plasma concentration by approximately 20% [1].

Common adverse effects documented in phase III trials include unpleasant taste (reported in up to 34% of participants), dizziness (up to 7%), and somnolence (up to 10%) [2]. Residual sedation the following morning is dose-dependent; the 3 mg dose carries a higher risk of next-morning impairment than the 1 mg dose [1].

Tolerance to eszopiclone's hypnotic effect does not appear to develop over 6 months of nightly use based on the Krystal et al. data [2]. Dependence and withdrawal are possible with abrupt discontinuation after prolonged use; tapering is preferred [7].

Insurance, Prior Authorization, and Cost in New Hampshire

Most commercial health insurance plans covering New Hampshire residents require prior authorization (PA) before dispensing eszopiclone, particularly the brand-name Lunesta [13]. Generic eszopiclone faces fewer PA requirements but is not universally covered without step therapy documentation.

NH Medicaid does not cover eszopiclone for insomnia as of 2025. Patients on NH Medicaid who need a sleep medication should discuss alternatives covered under the NH preferred drug list with their prescriber [14].

A standard PA request for eszopiclone in New Hampshire typically requires:

• Diagnosis of chronic insomnia disorder with ICD-10 code G47.00
• Documentation that sleep hygiene counseling was attempted
• Failure of or contraindication to at least one generic hypnotic (commonly doxepin, zolpidem, or trazodone, depending on plan formulary)
• Duration-of-symptoms documentation (minimum 3 months for most plans) [13]

PA decisions typically take 3 to 5 business days for standard requests and 24 to 72 hours for urgent requests under NH insurance regulations [13]. Denials can be appealed; first-level appeals succeed approximately 40% to 60% of the time when supported by clinical notes documenting prior treatment failure [13].

Patients paying cash can use GoodRx or manufacturer discount programs. Generic eszopiclone 3 mg (30 tablets) has been available at NH pharmacies for as low as $18 with discount coupons as of mid-2025.

New Hampshire Pharmacy Access and 503A Compounding

Every major retail pharmacy chain operating in New Hampshire, including CVS, Walgreens, Rite Aid, Hannaford, and Walmart Pharmacy, stocks generic eszopiclone tablets in all three FDA-approved strengths [1]. Independent community pharmacies across NH also carry the drug.

503A compounding pharmacies licensed in New Hampshire may compound eszopiclone preparations for individual patients when a prescriber documents a specific clinical need that the commercially available tablets cannot meet [15]. Examples include patients with tablet-swallowing difficulty who need a liquid suspension or patients with documented sensitivity to excipients in commercially available tablets [15].

The FDA distinguishes 503A pharmacies (patient-specific compounding) from 503B outsourcing facilities (larger-scale compounding) [15]. Eszopiclone is not on the FDA's 503B-eligible bulk drug substance list, so large-scale compounded eszopiclone is not available through outsourcing facilities [15]. A 503A NH-licensed pharmacy can compound eszopiclone upon receipt of a valid patient-specific prescription from a DEA-registered prescriber [15].

Compounded eszopiclone formulations are not FDA-approved and lack the bioequivalence data of manufactured tablets. Prescribers ordering compounded eszopiclone should document the clinical rationale in the medical record [15].

Transferring a Lunesta Prescription to New Hampshire

Patients moving to New Hampshire from another state with an existing eszopiclone prescription can have it transferred to an NH pharmacy under specific conditions. Schedule IV prescriptions may be transferred between pharmacies exactly once under federal law [7]. After a single transfer, a new prescription from an NH-licensed prescriber is required [7].

If a patient's original prescriber is not licensed in New Hampshire, the prescription cannot simply be refilled at an NH pharmacy after the transfer. The patient will need an evaluation with a New Hampshire-licensed prescriber, which may be conducted via telehealth video visit in accordance with DEA and NH regulations [10].

The NH PDMP will query the prescription history from other states through the PMP InterConnect network, which connects 46 state PDMP databases as of 2024 [11]. An NH prescriber can see a patient's out-of-state controlled substance history before issuing a new prescription [11].

What Labs and Diagnostics Are Needed Before Eszopiclone in New Hampshire

No mandatory blood tests are required before prescribing eszopiclone. A standard clinical evaluation is sufficient [5]. Prescribers may order or recommend specific assessments based on clinical findings.

Useful pre-treatment evaluations include:

• Thyroid function tests (TSH) when hyperthyroidism may be contributing to insomnia
• Complete blood count and metabolic panel in patients with chronic fatigue or suspected comorbid conditions affecting sleep
• Polysomnography when OSA is suspected on clinical screening (STOP-BANG score 5 or higher) [12]; untreated moderate-to-severe OSA is a relative contraindication to sedative-hypnotics
• Epworth Sleepiness Scale to quantify daytime impairment [6]

The AASM practice guideline for chronic insomnia does not list laboratory tests as a routine pre-treatment requirement but does emphasize ruling out secondary causes of insomnia before initiating pharmacotherapy [5]. A prescriber who skips OSA screening before prescribing eszopiclone to a high-risk patient may be practicing below the standard of care given the interaction between sedative-hypnotics and respiratory depression in OSA [12].

Safety Considerations and Drug Interactions

Eszopiclone carries FDA boxed warning language shared by all sedative-hypnotic drugs: complex sleep behaviors including sleepwalking, sleep driving, and other activities while not fully awake have been reported and may cause serious injury or death [1]. Patients with a prior episode of complex sleep behavior while taking any sedative-hypnotic should not receive eszopiclone [1].

CNS depressants, including opioids, benzodiazepines, alcohol, and first-generation antihistamines, increase the risk of respiratory depression and excessive sedation when combined with eszopiclone [1]. CYP3A4 inhibitors such as ketoconazole, clarithromycin, and ritonavir can increase eszopiclone plasma concentrations substantially; dose reduction to 1 mg is recommended when these agents are co-administered [1]. CYP3A4 inducers such as rifampin reduce eszopiclone exposure and may reduce efficacy [1].

Eszopiclone use during pregnancy has not been adequately studied in humans [1]. It is classified as FDA Pregnancy Category C based on animal data showing fetal effects at high doses [1]. Prescribers should use caution and document the risk-benefit discussion in the medical record when treating pregnant patients.

A 2023 observational cohort analysis published in JAMA Internal Medicine found that benzodiazepine receptor agonists (BZRAs) including eszopiclone were associated with a modest but statistically significant increase in fall risk among adults over age 65 (adjusted odds ratio 1.34 to 95% CI 1.18 to 1.52) [16]. New Hampshire prescribers treating older adults should weigh this risk against the documented harms of untreated chronic insomnia, including increased cardiovascular and metabolic disease risk [6].

Cognitive Behavioral Therapy for Insomnia as an Adjunct or Alternative

AASM guidelines designate CBT-I as the preferred first-line treatment for chronic insomnia disorder, ahead of pharmacotherapy [5]. The guideline states: "We recommend that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults." CBT-I typically involves 6 to 8 structured sessions covering sleep restriction therapy, stimulus control, sleep hygiene, relaxation techniques, and cognitive restructuring [5].

A Cochrane systematic review of 20 randomized controlled trials (N=1,162) found that CBT-I produced a mean reduction in sleep onset latency of 19.03 minutes and a mean reduction in wake after sleep onset of 26.00 minutes compared with control conditions [17]. These effect sizes are comparable to those produced by pharmacotherapy, with the added advantage that CBT-I effects persist after treatment ends, while drug effects generally cease when the drug is stopped [17].

Many New Hampshire patients begin eszopiclone while completing a CBT-I program, using the medication to provide short-term relief while building long-term behavioral sleep skills. This combination approach has been studied specifically: Morin et al. (2009, N=160) found that combined CBT-I plus pharmacotherapy produced superior short-term outcomes but that patients who received CBT-I alone or combined therapy maintained better long-term outcomes than those who received pharmacotherapy alone [18].

Digital CBT-I (dCBT-I) programs such as Sleepio and SHUTi are accessible to New Hampshire residents without an in-person clinic visit and may be covered by some NH commercial plans [19].

Step-by-Step: Getting Your Eszopiclone Prescription in New Hampshire

The practical sequence for a New Hampshire resident seeking eszopiclone:

Step 1. Choose a prescriber. Select an in-person NH provider or a telehealth platform with NH-licensed prescribers holding active DEA numbers.

Step 2. Prepare documentation. Gather a 7-day sleep diary, a list of current medications, and any prior treatment records (CBT-I completion, prior sleep medications, sleep study results if applicable).

Step 3. Complete the visit. A synchronous audio-video appointment is required for a new controlled substance prescription through telehealth [10]. The visit typically lasts 20 to 30 minutes.

Step 4. PDMP query. Your prescriber will query the NH PDMP in real time during or immediately before the visit [11]. This adds no time from your perspective.

Step 5. Prescription transmission. The prescriber transmits an electronic prescription to your chosen NH pharmacy. Most NH pharmacies can fill it same-day or next-day.

Step 6. Insurance or PA check. If your insurance requires PA, your prescriber's office submits the documentation. Standard PA turnaround is 3 to 5 business days [13].

Step 7. Pick up or arrange delivery. Many NH pharmacies offer mail delivery within the state. Schedule IV drugs may be mailed by licensed pharmacies under DEA 21 CFR Part 1301 [7].

Follow-up appointments are typically scheduled at 4 weeks to assess response and tolerability, then every 3 months for ongoing prescribing [5].